Anche quest’anno il gruppo GIMEMA partecipa al congresso della Società americana di ematologia (ASH – American Society of Hematology) con una ricca serie di lavori sulle malattie onco-ematologica.
L’edizione numero 66 del congresso si terrà per il 2024 dal 7 al 10 dicembre a San Diego, in California, sia in presenza sia in modalità online. Il GIMEMA sarà presente con suoi lavori e ricercatori. L’evento ospiterà oltre 30.000 professionisti della salute, medici, ricercatori, educatori, più di 275 espositori e più di 5 mila abstract presentati. Il programma è consultabile sul sito dell’ASH, oltre che attraverso l’applicazione mobile dell’ASH.
I ricercatori GIMEMA partecipano con abstract su leucemia linfoblastica acuta, leucemia mieloide acuta, leucemia mieloide cronica, qualità di vita, leucemia linfoide cronica e linfoma non-Hodgkin.
Di seguito la lista degli abstract GIMEMA che verranno presentati al congresso ASH2024:
Leucemia linfoblastica acuta
Orale:
- 835 – Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
Chiaretti S, et al.
- 274 – Digital Twins As Control Groups to AccelerateAssessment of Safety and Effi cacy of NovelTreatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia
Piciocchi A, et al.
Poster:
- 2836 – Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
Beldinanzi M, et al.
Leucemia mieloide acuta
Orale:
- 65 – Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients
Bartalucci N, et al.
Poster:
- 2891 – Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
Marconi G, et al.
- 1574 – Centralized MRD Assessment in GIMEMA AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined withIntensified FLAI Chemotherapy (V-FLAI) as Induction Therapy of non Low-Risk AML
Minetto P, et al.
- 2893 – Venetoclax and Azacitidine for Relapse Prevention in NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial
Sartor C, et al.
Leucemia mieloide cronica
Orale:
- 992 – Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the GIMEMA LabNet Network
Stagno F, et al.
Poster:
- 4530 – Evaluating the Impact of Cross-Over from imatinib to nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: results from the GIMEMA Sustrenim study
Piciocchi A, et al.
- 2427 – Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)
Breccia M, et al.
Qualità di vita
Orale:
- 407 – Profiling Baseline Health-Related Quality of Life of Patients with Newly Diagnosed Myeloid Malignancies: A Pooled Analysis of 3349 Patients with AML, APL and MDS from the International Proactive Project
Efficace F, et al.
- 404 – The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema
Efficace F, et al.
Leucemia linfoide cronica e linfoma non-Hodgkin
Poster: